Korean medical AI company Lunit said Tuesday it has signed a supply agreement with GC i-Med, a subsidiary of GC Biopharma specializing in comprehensive health check-ups, to provide its AI-powered imaging solutions for use in routine screenings.

Under the agreement, Lunit’s chest X-ray analysis tool (INSIGHT CXR) and mammography analysis tool (INSIGHT MMG) will be deployed at GC i-Med’s Gangnam and Gangbuk clinics, which are part of the GC Medical Science network.

The company said this marks the first time its AI solutions will be used as non-reimbursed services in a health screening setting. Previously, the software had only been applied in outpatient diagnostics at hospitals, also on a non-reimbursed basis. The expansion, Lunit said, could help accelerate adoption of AI-based medical technologies across preventive care settings.

For breast cancer screening, patients will receive an AI-generated report alongside their routine health check-up results. The report includes screening findings and a QR code linking to additional guidance and prevention tips.